TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03762629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
Study: NCT03240939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride 0.5 mg
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5 mg
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-201
Description: single dose
Study: NCT03464604

Intervention type: DIAGNOSTIC_TEST
Intervention: active
Description: Pre-screening for melanoma by qualified nurse
Study: NCT03241524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program for pelvic muscle floor
Description: Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
Study: NCT03109340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised treadmill group (Group I)
Description: An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECE PEDO pedometer (Group II)
Description: Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
Study: NCT02023879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

Intervention type: DRUG
Group type: OTHER
Intervention: Alirocumab
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Alirocumab)
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Alirocumab)
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-statin LMT
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Non-statin LMT
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-statin LMT
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study: NCT01243073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Study: NCT01671748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST ultrasound therapy
Description: Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Compression bandaging, non-adherent dressing, and debridement if required.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Compression bandaging, non-adherent dressing, and debridement if required.
Study: NCT02344394

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Cryoballoon
Description: For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
Study: NCT04469452

Intervention type: DEVICE
Intervention: Apollo Device
Description: Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
Study: NCT01915992

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Study: NCT02990364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Topical Product
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Topical Product
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Topical Product
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Topical Product
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
Study: NCT03180008

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fit and Strong!
Description: Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong! Plus
Description: The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
Study: NCT04093466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1003
Description: Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
Study: NCT04473118

Intervention type: OTHER
Intervention: Survey
Description: An online-based questionnaire sent to participants via email
Study: NCT03792789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mCIMT with real rTMS
Description: Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: mCIMT with sham rTMS
Description: Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil.
Study: NCT00985530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
Study: NCT02453802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp
Description: Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp
Description: IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Topical 160 ml normal saline application after closure of joint capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Topical 160 ml normal saline application after closure of joint capsule.
Study: NCT04463056

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Soliris®
Description: Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
Study: NCT00438243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac (Xibrom)
Description: 1 drop to affected eye twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Plus
Description: 1 drop in the affected eye twice daily
Study: NCT02968433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusions of young plasma
Description: Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
Study: NCT02231879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor
Description: Twice daily low dose injection for 14 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor
Description: Twice daily low dose injection for 14 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Twice daily low dose injection for 14 months.
Study: NCT02091297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia
Study: NCT02231879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Twice daily low dose injection for 14 months.
Study: NCT04393220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: 15mg/kg (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: 15mg/kg (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 480 mg IV infusions for 30 minutes q4w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 480 mg IV infusions for 30 minutes q4w
Study: NCT05525442

Intervention type: PROCEDURE
Intervention: percutaneous cholecystostomy
Description: Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.

Intervention type: PROCEDURE
Intervention: percutaneous cholecystostomy
Description: Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
Study: NCT01171781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin (3 weekly)
Description: radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin (weekly)
Description: radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
Study: NCT01088880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study: NCT01073228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02091297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT02730377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-glucosidase inhibitors
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitors
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meglitinides
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT-2 inhibitors
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazolidinediones
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study: NCT02402023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: CM is standard care plus monetary payment delivered contingent on abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care (SC)
Description: Standard of care consists of smoking cessation counseling sessions and nicotine patches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SC)
Description: Standard of care consists of smoking cessation counseling sessions and nicotine patches.
Study: NCT01328899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC) (PneumRx's)
Description: Lung Volume Reduction Coil
Study: NCT01846481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-8000 100 mg
Description: RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-8000 100 mg
Description: RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: 50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: 50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: 50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: 50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-8000 200 mg
Description: RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-8000 200 mg
Description: RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
Study: NCT02928783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Study: NCT03747068

Intervention type: DRUG
Intervention: Anti-TNF Drug